EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Variant rs7665090 Is Associated With Interferon‐Beta Response in Multiple Sclerosis Patients

Andreu Vilaseca iD, Elena Urcelay, Sunny Malhotra, Mireia Castillo, Montserrat Aroca, Angela Vidal-Jordana iD, Agustín Pappolla, René Carvajal, Georgina Arrambide, Adela González-Jiménez, Irene Gómez-Delgado, Alvaro Cobo-Calvo und 14 weitere

European Journal of Neurology · 2025

DOI: 10.1111/ene.70227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Andreu Vilaseca und 25 weiteren Autor:innen. Beteiligte Einrichtung: Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebro…. Hauptthemen laut MEDLINE: Interferon-beta, Multiple Sclerosis, Immunologic Factors, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

GG homozygosity for the risk gene variant rs7665090 has been reported to enhance nuclear factor kappa B (NFκB) activity in T cells from multiple sclerosis (MS) patients. Here, we investigated the association between this polymorphism and the response to different disease‐modifying therapies in MS.

Methods

The rs7665090 polymorphism was genotyped in 558 MS patients treated with injectable therapies [IFNβ ( n = 213) and glatiramer acetate ( n = 55)], oral therapies [dimethylfumarate ( n = 97), teriflunomide ( n = 41), and fingolimod ( n = 37)], and natalizumab ( n = 115). Treatment response was assessed after 1 year for injectable therapies using the Rio Score, which considers relapses, EDSS progression, and radiological activity on MRI. For oral therapies and natalizumab, response was evaluated after 2 years based on clinical and radiological disease activity. Univariable and multivariable logistic regression analyses were performed to assess treatment response for each therapy independently.

Results

GG homozygosity was associated with a favorable response outcome in patients treated with IFNβ in the multivariable analysis after adjusting for age and EDSS at treatment onset [OR 0.42 (0.18–0.94); p = 0.037]. This finding was restricted to MS patients carrying the GG risk genotype and seemed specific for IFNβ treatment, since the rs7665090 polymorphism did not influence the response to the other MS therapies.

Conclusion

The polymorphism rs7665090 is associated with a favorable response to IFNβ. This study illustrates how genotyping this polymorphism could serve as a useful biomarker in clinical practice to help identify MS patients who are likely to respond favorably to treatment, and encourages further replication in larger cohorts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interferon-betaMultiple SclerosisImmunologic FactorsPolymorphism, Single NucleotideHumansMaleFemaleAdultMiddle AgedTreatment OutcomeNitrilesGenotypeNatalizumabFingolimod Hydrochloride

Stichwörter der Autor:innen

biomarkersgeneticsinterferonmultiple sclerosisnuclear factor kappa Btreatment response

Substanzen

Interferon-betaImmunologic FactorsNitrilesNatalizumabFingolimod Hydrochloride

Autor:innen und Institutionen

  • Servei de Neurologia, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Institut de Recerca Vall d'Hebron (VHIR), Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain.
  • Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED) - ISCIII, Madrid, Spain.

ORCID-Profile: Andreu Vilaseca, Angela Vidal-Jordana, Ana Zabalza, Luciana Midaglia, Jaume Sastre-Garriga, Jordi Río, Manuel Comabella

Zitieren

APA

Vilaseca, A., Urcelay, E., Malhotra, S., Castillo, M., Aroca, M., Vidal-Jordana, A., Pappolla, A., Carvajal, R., Arrambide, G., González-Jiménez, A., Gómez-Delgado, I., Cobo-Calvo, A., Mongay-Ochoa, N., Rodriguez-Acevedo, B., Tur, C., Villacieros-Álvarez, J., Ariño, H., Castilló, J., Zabalza, A., …, & Comabella, M. (2025). The Variant rs7665090 Is Associated With Interferon‐Beta Response in Multiple Sclerosis Patients. European Journal of Neurology. https://doi.org/10.1111/ene.70227

Vancouver

Vilaseca A, Urcelay E, Malhotra S, Castillo M, Aroca M, Vidal-Jordana A, et al. The Variant rs7665090 Is Associated With Interferon‐Beta Response in Multiple Sclerosis Patients. European Journal of Neurology. 2025. doi:10.1111/ene.70227

BibTeX
@article{Vilaseca2025,
  author = {Vilaseca, Andreu and Urcelay, Elena and Malhotra, Sunny and Castillo, Mireia and Aroca, Montserrat and Vidal-Jordana, Angela and Pappolla, Agustín and Carvajal, René and Arrambide, Georgina and González-Jiménez, Adela and Gómez-Delgado, Irene and Cobo-Calvo, Alvaro and Mongay-Ochoa, Neus and Rodriguez-Acevedo, Breogan and Tur, Carmen and Villacieros-Álvarez, Javier and Ariño, Helena and Castilló, Joaquín and Zabalza, Ana and Midaglia, Luciana and La Puma, Delon and Sastre-Garriga, Jaume and Tintoré, Mar and Río, Jordi and Montalban, Xavier and Comabella, Manuel},
  title = {The Variant rs7665090 Is Associated With Interferon‐Beta Response in Multiple Sclerosis Patients},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70227}
}
Kostenlos starten →